Loxapine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Loxapine" in English language version.

refsWebsite

Global rank English rank

15nih.gov

4^th place

10doi.org

2^nd place

4semanticscholar.org

11^th place

8^th place

2fda.gov

447^th place

338^th place

1in.gov.br

3,151^st place

5,932^nd place

1web.archive.org

1^st place

1psychiatrist.com

low place

1adasuve.com

low place

1unc.edu

1,538^th place

1,042^nd place

adasuve.com

"ADASUVE Package Insert" (PDF). Galen US Inc.

doi.org

Popovic D, Nuss P, Vieta E (2015-04-01). "Revisiting loxapine: a systematic review". Annals of General Psychiatry. 14: 15. doi:10.1186/s12991-015-0053-3. PMC 4391595. PMID 25859275.
Cheung SW, Tang SW, Remington G (March 1991). "Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography". Journal of Chromatography. 564 (1): 213–221. doi:10.1016/0378-4347(91)80083-O. PMID 1860915.
"Clozapine and loxapine for schizophrenia". Drug and Therapeutics Bulletin. 29 (11): 41–42. May 1991. doi:10.1136/dtb.29.11.41. PMID 1747161. S2CID 27613339.
Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007). Chakrabarti A (ed.). "Loxapine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (4): CD001943. doi:10.1002/14651858.CD001943.pub2. PMC 7017975. PMID 17943763.
Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007). "Loxapine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (4): CD001943. doi:10.1002/14651858.CD001943.pub2. PMC 7017975. PMID 17943763.
Nordstrom K (2012). "Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: An update". Neuropsychiatry. 2 (3): 253–260. doi:10.2217/npy.12.23. S2CID 39718567.
DePaulo JR, Ayd FJ (March 1982). "Loxapine: fifteen years' clinical experience". Psychosomatics. 23 (3): 261–271. doi:10.1016/S0033-3182(82)73416-4. PMID 7041162.
Sperry L, Hudson B, Chan CH (March 1984). "Loxapine abuse". The New England Journal of Medicine. 310 (9): 598. doi:10.1056/NEJM198403013100920. PMID 6694719.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–170. doi:10.1007/s00210-011-0704-0. PMID 22033803. S2CID 14274150.
Simpson GM, Cooper TB, Lee JH, Young MA (March 1978). "Clinical and plasma level characteristics of intramuscular and oral loxapine". Psychopharmacology. 56 (2): 225–232. doi:10.1007/BF00431855. PMID 417377. S2CID 21795809.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

accessdata.fda.gov

"LOXITANE Package Insert" (PDF). Watson Laboratories, Inc.

in.gov.br

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

nih.gov

pubmed.ncbi.nlm.nih.gov

Popovic D, Nuss P, Vieta E (2015-04-01). "Revisiting loxapine: a systematic review". Annals of General Psychiatry. 14: 15. doi:10.1186/s12991-015-0053-3. PMC 4391595. PMID 25859275.
Glazer WM (1999). "Does loxapine have "atypical" properties? Clinical evidence". The Journal of Clinical Psychiatry. 60 (Suppl 10): 42–46. PMID 10340686.
Cheung SW, Tang SW, Remington G (March 1991). "Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography". Journal of Chromatography. 564 (1): 213–221. doi:10.1016/0378-4347(91)80083-O. PMID 1860915.
"Clozapine and loxapine for schizophrenia". Drug and Therapeutics Bulletin. 29 (11): 41–42. May 1991. doi:10.1136/dtb.29.11.41. PMID 1747161. S2CID 27613339.
Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007). Chakrabarti A (ed.). "Loxapine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (4): CD001943. doi:10.1002/14651858.CD001943.pub2. PMC 7017975. PMID 17943763.
Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007). "Loxapine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (4): CD001943. doi:10.1002/14651858.CD001943.pub2. PMC 7017975. PMID 17943763.
DePaulo JR, Ayd FJ (March 1982). "Loxapine: fifteen years' clinical experience". Psychosomatics. 23 (3): 261–271. doi:10.1016/S0033-3182(82)73416-4. PMID 7041162.
Singh AN, Barlas C, Singh S, Franks P, Mishra RK (January 1996). "A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes". Journal of Psychiatry & Neuroscience. 21 (1): 29–35. PMC 1188731. PMID 8580115.
Sperry L, Hudson B, Chan CH (March 1984). "Loxapine abuse". The New England Journal of Medicine. 310 (9): 598. doi:10.1056/NEJM198403013100920. PMID 6694719.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–170. doi:10.1007/s00210-011-0704-0. PMID 22033803. S2CID 14274150.
Simpson GM, Cooper TB, Lee JH, Young MA (March 1978). "Clinical and plasma level characteristics of intramuscular and oral loxapine". Psychopharmacology. 56 (2): 225–232. doi:10.1007/BF00431855. PMID 417377. S2CID 21795809.

ncbi.nlm.nih.gov

Popovic D, Nuss P, Vieta E (2015-04-01). "Revisiting loxapine: a systematic review". Annals of General Psychiatry. 14: 15. doi:10.1186/s12991-015-0053-3. PMC 4391595. PMID 25859275.
Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007). Chakrabarti A (ed.). "Loxapine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (4): CD001943. doi:10.1002/14651858.CD001943.pub2. PMC 7017975. PMID 17943763.
Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007). "Loxapine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (4): CD001943. doi:10.1002/14651858.CD001943.pub2. PMC 7017975. PMID 17943763.
Singh AN, Barlas C, Singh S, Franks P, Mishra RK (January 1996). "A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes". Journal of Psychiatry & Neuroscience. 21 (1): 29–35. PMC 1188731. PMID 8580115.

psychiatrist.com

Glazer WM (1999). "Does loxapine have "atypical" properties? Clinical evidence". The Journal of Clinical Psychiatry. 60 (Suppl 10): 42–46. PMID 10340686.

semanticscholar.org

api.semanticscholar.org

"Clozapine and loxapine for schizophrenia". Drug and Therapeutics Bulletin. 29 (11): 41–42. May 1991. doi:10.1136/dtb.29.11.41. PMID 1747161. S2CID 27613339.
Nordstrom K (2012). "Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: An update". Neuropsychiatry. 2 (3): 253–260. doi:10.2217/npy.12.23. S2CID 39718567.
Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–170. doi:10.1007/s00210-011-0704-0. PMID 22033803. S2CID 14274150.
Simpson GM, Cooper TB, Lee JH, Young MA (March 1978). "Clinical and plasma level characteristics of intramuscular and oral loxapine". Psychopharmacology. 56 (2): 225–232. doi:10.1007/BF00431855. PMID 417377. S2CID 21795809.

unc.edu

kidbdev.med.unc.edu

Roth BL, Driscol J. "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.

web.archive.org

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.